- Home
- EDRY vs SABS Comparison
EDRY vs SABS Comparison
Compare EDRY & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- SABS
- Stock Information
- Founded
- EDRY 2018
- SABS 2014
- Country
- EDRY Greece
- SABS United States
- Employees
- EDRY N/A
- SABS N/A
- Industry
- EDRY Marine Transportation
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- SABS Health Care
- Exchange
- EDRY Nasdaq
- SABS Nasdaq
- Market Cap
- EDRY 38.5M
- SABS 32.1M
- IPO Year
- EDRY N/A
- SABS N/A
- Fundamental
- Price
- EDRY $11.38
- SABS $3.53
- Analyst Decision
- EDRY
- SABS Strong Buy
- Analyst Count
- EDRY 0
- SABS 5
- Target Price
- EDRY N/A
- SABS $12.40
- AVG Volume (30 Days)
- EDRY 11.1K
- SABS 69.6K
- Earning Date
- EDRY 02-13-2025
- SABS 11-06-2024
- Dividend Yield
- EDRY N/A
- SABS N/A
- EPS Growth
- EDRY N/A
- SABS N/A
- EPS
- EDRY N/A
- SABS N/A
- Revenue
- EDRY $65,085,280.00
- SABS $1,512,723.00
- Revenue This Year
- EDRY $34.61
- SABS N/A
- Revenue Next Year
- EDRY $15.93
- SABS N/A
- P/E Ratio
- EDRY N/A
- SABS N/A
- Revenue Growth
- EDRY 39.04
- SABS N/A
- 52 Week Low
- EDRY $10.04
- SABS $2.16
- 52 Week High
- EDRY $24.84
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- EDRY 43.15
- SABS 46.39
- Support Level
- EDRY $11.43
- SABS $3.50
- Resistance Level
- EDRY $11.80
- SABS $4.35
- Average True Range (ATR)
- EDRY 0.50
- SABS 0.41
- MACD
- EDRY 0.21
- SABS -0.07
- Stochastic Oscillator
- EDRY 66.22
- SABS 19.22
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.